Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avadel Pharmaceuticals Plc ADR (AVDL)

Avadel Pharmaceuticals Plc ADR (AVDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,429,711
  • Shares Outstanding, K 89,806
  • Annual Sales, $ 27,960 K
  • Annual Income, $ -160,280 K
  • 60-Month Beta 1.56
  • Price/Sales 51.71
  • Price/Cash Flow N/A
  • Price/Book 16.49
Trade AVDL with:

Options Overview Details

View History
  • Implied Volatility 58.66% ( +2.00%)
  • Historical Volatility 65.83%
  • IV Percentile 6%
  • IV Rank 12.51%
  • IV High 110.15% on 03/01/24
  • IV Low 51.29% on 08/30/23
  • Put/Call Vol Ratio 0.15
  • Today's Volume 1,342
  • Volume Avg (30-Day) 6,348
  • Put/Call OI Ratio 1.42
  • Today's Open Interest 55,001
  • Open Int (30-Day) 56,611

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.31
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.82 +33.42%
on 03/04/24
17.00 -7.24%
on 03/04/24
+2.20 (+16.21%)
since 02/16/24
3-Month
11.82 +33.42%
on 03/04/24
17.24 -8.53%
on 01/08/24
+1.91 (+13.78%)
since 12/18/23
52-Week
8.00 +97.13%
on 03/30/23
17.24 -8.53%
on 01/08/24
+6.86 (+76.99%)
since 03/17/23

Most Recent Stories

More News
Avadel: Q3 Earnings Snapshot

Avadel: Q3 Earnings Snapshot

AVDL : 15.77 (-0.94%)
Avadel: Q2 Earnings Snapshot

Avadel: Q2 Earnings Snapshot

AVDL : 15.77 (-0.94%)
Why Shares of Avadel Soared This Week

The company got its first FDA approval.

JAZZ : 123.41 (+2.08%)
AVDL : 15.77 (-0.94%)
Avadel: Q1 Earnings Snapshot

Avadel: Q1 Earnings Snapshot

AVDL : 15.77 (-0.94%)
Avadel: Q4 Earnings Snapshot

Avadel: Q4 Earnings Snapshot

AVDL : 15.77 (-0.94%)
Avadel: Q3 Earnings Snapshot

Avadel: Q3 Earnings Snapshot

AVDL : 15.77 (-0.94%)
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Received tentative approval for LUMRYZâ„¢ (sodium oxybate) extended-release for oral suspension from FDA on July 18Advancing key activities to potentially...

AVDL : 15.77 (-0.94%)
Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive...

AVDL : 15.77 (-0.94%)
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

AVDL : 15.77 (-0.94%)
Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZâ„¢ (sodium oxybate) extended-release oral suspension

- Validates the safety profile and clinical efficacy of LUMRYZ - Pursuing strategies to accelerate final approval DUBLIN, Ireland, July 19, 2022 (GLOBE...

AVDL : 15.77 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

3rd Resistance Point 16.41
2nd Resistance Point 16.26
1st Resistance Point 16.01
Last Price 15.77
1st Support Level 15.61
2nd Support Level 15.46
3rd Support Level 15.21

See More

52-Week High 17.24
Last Price 15.77
Fibonacci 61.8% 13.71
Fibonacci 50% 12.62
Fibonacci 38.2% 11.53
52-Week Low 8.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar